Foghorn Therapeutics Stock Analysis
| FHTX Stock | USD 5.01 0.09 1.76% |
Foghorn Therapeutics is undervalued with Real Value of 6.76 and Hype Value of 5.05. The main objective of Foghorn Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Foghorn Therapeutics is worth, separate from its market price. There are two main types of Foghorn Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Foghorn Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Foghorn Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Foghorn Stock trading window is adjusted to America/New York timezone.
Foghorn |
Foghorn Stock Analysis Notes
About 23.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.85. Foghorn Therapeutics had not issued any dividends in recent years. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To learn more about Foghorn Therapeutics call Adrian Gottschalk at 617 586 3100 or check out https://foghorntx.com.Foghorn Therapeutics Investment Alerts
| Foghorn Therapeutics generated a negative expected return over the last 90 days | |
| Foghorn Therapeutics has high historical volatility and very poor performance | |
| Foghorn Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 34.16 M. Net Loss for the year was (98.43 M) with loss before overhead, payroll, taxes, and interest of (82.3 M). | |
| Foghorn Therapeutics currently holds about 373.5 M in cash with (118.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Foghorn Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors |
Foghorn Therapeutics Upcoming and Recent Events
Earnings reports are used by Foghorn Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Foghorn Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 283.62 M.Technical Drivers
As of the 26th of February, Foghorn Therapeutics shows the Mean Deviation of 3.74, variance of 25.88, and Standard Deviation of 5.09. Foghorn Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Foghorn Therapeutics Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Foghorn Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Foghorn Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Foghorn Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Foghorn Therapeutics Outstanding Bonds
Foghorn Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Foghorn Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Foghorn bonds can be classified according to their maturity, which is the date when Foghorn Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Foghorn Therapeutics Predictive Daily Indicators
Foghorn Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Foghorn Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Foghorn Therapeutics Forecast Models
Foghorn Therapeutics' time-series forecasting models are one of many Foghorn Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Foghorn Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Foghorn Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Foghorn Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Foghorn shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Foghorn Therapeutics. By using and applying Foghorn Stock analysis, traders can create a robust methodology for identifying Foghorn entry and exit points for their positions.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Foghorn Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.